Outlook Therapeutics (OTLK) has moved back into focus after resubmitting its Biologics License Application to the FDA for ONS-5010/LYTENAVA for wet age related macular degeneration, following a successful appeal of a prior Complete Response Letter.

Investors appear to be reacting to the BLA resubmission and upcoming FDA decision. The latest share price is US$1.10, with a 30 day share price return of 353.61%. However, the 1 year total shareholder return is down 40.22%, highlighting that recent momentum contrasts with a much weaker longer term record.

If this kind of regulatory driven move has your attention, it may be a good moment to broaden your search and check out 40 healthcare AI stocks

With the share price up sharply in just a month, yet the 1 year return still materially lower, the key question is whether Outlook Therapeutics remains mispriced or if the market is already baking in the potential FDA outcome.

Preferred Multiple of price to book: Is it justified?

On the latest figures, Outlook Therapeutics trades on a P/B ratio of roughly 4.6x in absolute terms, but that number is complicated by one key fact: shareholders equity is negative, with liabilities exceeding assets.

P/B is usually a quick way to compare a company’s market value to its net assets. Yet when equity is negative the signal becomes distorted and can easily mislead. In this case, the standard multiple stops being a clean shortcut and starts to reflect balance sheet stress more than any simple valuation read across.

Relative to peers, Outlook Therapeutics sits in a very different position. The US Biotechs industry average P/B is 2.3x, and the direct peer average referenced here is 1.3x, both supported by positive equity. Outlook Therapeutics instead combines a much higher implied multiple with negative equity and only $333k in revenue, which paints a far more fragile financial picture than a headline P/B comparison might suggest.

Result: Price-to-book ratio of 4.6x (ABOUT RIGHT).

However, there are still clear pressure points here, including ongoing losses of US$60.96m on revenue of just US$0.33m and a multi year total return record that remains deeply negative.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With all this in mind, sentiment is clearly split, so it makes sense to move quickly, review the data yourself and weigh both the 1 key reward and 5 important warning signs.

Looking for more investment ideas?

If one regulatory story has you watching closely, do not stop here. Widen your watchlist with fresh ideas that could reshape how your portfolio looks.

• Target potential value opportunities by scanning 46 high quality undervalued stocks that combine quality fundamentals with more appealing pricing.
• Strengthen your income stream by reviewing 8 dividend fortresses that focus on higher yielding companies.
• Dial back portfolio risk by checking 67 resilient stocks with low risk scores designed to spotlight more resilient stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.